Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer: Disease Control and Quality of Life at 8 Years

被引：1
|
作者：
Katz, A. [1 ]
Kang, J. [1 ]
机构：
[1] FROS Radiat Oncol & CyberKnife Ctr, Flushing, NY USA
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2015年 / 93卷 / 03期
关键词：
D O I：
10.1016/j.ijrobp.2015.07.1026
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2474
引用
收藏
页码：E187 / E187
页数：1
相关论文
共 50 条
  • [31] Outcomes of a Dose-Escalated Stereotactic Body Radiation Phase 1 Trial for Patients With Low- and Intermediate-Risk Prostate Cancer
    Potters, Louis
    Rana, Zaker
    Lee, Lucille
    Cox, Brett W.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 104 (02): : 334 - 342
  • [32] Prospective Evaluation of Stereotactic Body Radiation Therapy for Low- and Intermediate-risk Prostate Cancer: Emulating High-dose-rate Brachytherapy Dose Distribution
    Fuller, D. B.
    Mardirossian, G.
    Wong, D.
    Morris, D.
    Underhil, K.
    Medbery, C.
    Peddada, A.
    McKellar, H.
    Gray, J.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 84 (03): : S149 - S149
  • [33] A Prospective, Single-Arm, Phase II, Multi-Center Study of Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer
    Olson, A. C.
    Skiba, J. H.
    Gill, B. S.
    Wang, H.
    Davies, B.
    Holeva, K.
    D'Ambrosio, D.
    Wegner, R. E.
    Heron, D. E.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2021, 111 (03): : E288 - E289
  • [34] Quality of life outcomes from a multicenter study of SBRT for low- and intermediate-risk prostate cancer
    Meier, R.
    Kaplan, I.
    [J]. RADIOTHERAPY AND ONCOLOGY, 2014, 111 : S220 - S221
  • [35] Decreased PSA nadir as a result of dose-escalated stereotactic body radiation for patients with low- and intermediate-risk prostate cancer.
    Rana, Zaker Hamid
    Potters, Louis
    Lee, Lucille
    Cox, Brett W.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [36] Outcomes of a Dose-Escalated Stereotactic Body Radiation Phase I/II Trial for Patients With Low- and Intermediate-Risk Prostate Cancer
    Rana, Zaker
    Potters, Louis
    Lee, Lucille
    Cox, Brett
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 101 (02): : E8 - E8
  • [37] A Phase I Dose Escalation Study of Stereotactic Body Radiation Therapy (SBRT) for Low-and Intermediate-risk Prostate Cancer
    Boike, T. P.
    Cho, L.
    Lotan, Y.
    Perkins, A. A.
    Brindle, J.
    Pistenmaa, D. A.
    Timmerman, R. D.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 75 (03): : S80 - S80
  • [38] A Dosimetric and Clinical Evaluation of Monotherapy With Hypofractionated Stereotactic Body Radiation Therapy in the Treatment of Intermediate-Risk Prostate Cancer
    Ju, A. W.
    Suy, S.
    Lei, S.
    Oermann, E. K.
    Sherer, B. A.
    Hanscom, H. N.
    Kim, J. S.
    Lynch, J. H.
    Dritschilo, A.
    Collins, S. P.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 84 (03): : S827 - S827
  • [39] Testosterone kinetics after proton therapy for low- and intermediate-risk prostate cancer
    Nichols, Romaine Charles
    Morris, Christopher G.
    Hoppe, Bradford S.
    Henderson, Randal H.
    Mendenhall, William M.
    Li, Zuofeng
    Williams, Christopher R.
    Costa, Joseph A.
    Harris, Stephanie
    Mendenhall, Nancy Price
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [40] Biochemical disease control outcomes of stereotactic body radiation therapy (SBRT) or moderate hypo-fractionation (HFRT) for low- and intermediate-risk prostate cancer (PrCa): Retrospective analysis of 12 years of experience at two Canadian cancer centers.
    Hu, Hsin-Pei Spencer
    Gouran-Savadkoohi, Mohammad
    Anagnostopoulos, Gregory
    Dayes, Ian S.
    Ishkanian, Adrian
    Hallock, Abhirami
    Corbett, Thomas B.
    Lukka, Himanshu
    Quan, Kimmen
    Schnarr, Kara
    Cuthbert, David
    Goldberg, Mira
    Tsakiridis, Theodoros
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
12345